Clinical Trials Directory

Trials / Completed

CompletedNCT00014066

Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer

A Phase I Study of Photodynamic Therapy (PDT) Combined With High Dose Rate (HDR) Brachytherapy for Patients With Obstructive Bronchogenic Carcinoma

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
Sponsor
Roswell Park Cancer Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Photodynamic therapy uses light and drugs that make cnacer cells more sensitive to light to kill tumor cells. Brachytherapy uses radiation to damage tumor cells. Photodynamic therapy combined with brachytherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy plus brachytherapy in treating patients with recurrent lung cancer that is blocking the lung passages.

Detailed description

OBJECTIVES: I. Determine the feasibility, toxicity, and effectiveness of combination therapy with Photofrin PDT and HDT brachytherapy in patients with endobronchial obstructions from lung cancer. OUTLINE: This is not a randomized study. Photofrin solution is administered slowly as a bolus injection over 3-5 minutes on day 1. Bronchoscopy is performed under general anesthesia 48 hours after Photofrin injection. Light is transmitted from the laser to the tumor via quartz fiber optics (interstitial or surface PDT). Another bronchoscopy is performed 48 hours after PDT treatment to clean out any tissue debris left after PDT treatment. HDR brachytherapy is performed using prescribed dose of radiation for 5-10 minutes to designated positions. Repeat bronchoscopy is performed 3-4 weeks post HDR brachytherapy and a second HDR brachytherapy treatment may be given. Patients are followed every 3 months until death, or for 5 years. PROJECTED ACCRUAL: 16 patients will be entered over 1.5 years.

Conditions

Interventions

TypeNameDescription
DRUGhematoporphyrin derivative
RADIATIONbrachytherapy

Timeline

Start date
1993-03-01
Primary completion
2004-02-01
First posted
2004-02-04
Last updated
2013-02-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00014066. Inclusion in this directory is not an endorsement.